{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:16:15Z","timestamp":1784236575465,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1053\/j.ajkd.2018.09.016","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T02:07:31Z","timestamp":1545185251000},"page":"354-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan"],"prefix":"10.1053","volume":"73","author":[{"given":"Bart J.","family":"Kramers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maatje D.A.","family":"van Gastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy E.","family":"Boertien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1053\/j.ajkd.2018.09.016_bib1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9569","key":"10.1053\/j.ajkd.2018.09.016_bib2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.ajkd.2018.09.016_bib3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"issue":"25","key":"10.1053\/j.ajkd.2018.09.016_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2018.09.016_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.09.016_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2018.09.016_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2018.09.016_bib11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.09.016_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"issue":"4","key":"10.1053\/j.ajkd.2018.09.016_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1681\/ASN.V74567","article-title":"Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran","volume":"7","author":"Apperloo","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2018.09.016_bib14","first-page":"97","article-title":"A\u00a0radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow","volume":"20","author":"Donker","year":"1977","journal-title":"Neth J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.09.016_bib15","first-page":"303","article-title":"A\u00a0formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.ajkd.2018.09.016_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2018.09.016_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(01)00328-5","article-title":"Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects","volume":"51","author":"Bankir","year":"2001","journal-title":"Cardiovasc Res"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.09.016_bib19","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","article-title":"Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers","volume":"25","author":"Kim","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1053\/j.ajkd.2018.09.016_bib20","doi-asserted-by":"crossref","first-page":"e0169263","DOI":"10.1371\/journal.pone.0169263","article-title":"Urine concentrating capacity, vasopressin and copeptin in ADPKD and IgA nephropathy patients with renal impairment","volume":"12","author":"Zittema","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A\u00a0case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2018.09.016_bib22","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.09.016_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000463831","article-title":"Relationship between sodium intake and water intake: the false and the true","volume":"70","author":"Bankir","year":"2017","journal-title":"Ann Nutr Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2018.09.016_bib24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00394-015-0923-0","article-title":"Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes","volume":"55","author":"Ogna","year":"2016","journal-title":"Eur J Nutr"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2007091042","article-title":"Impact of solute intake on urine flow and water excretion","volume":"19","author":"Berl","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.09.016_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-physiol-021113-170350","article-title":"Advances in understanding the urine-concentrating mechanism","volume":"76","author":"Sands","year":"2014","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"10.1053\/j.ajkd.2018.09.016_bib27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrneph.2015.89","article-title":"Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus","volume":"11","author":"Bockenhauer","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.09.016_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618310618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618310618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:21:46Z","timestamp":1775319706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618310618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0272638618310618"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.09.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}